Gadolinium Linked to Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic Fibrosing Dermopathy (NFD)

Since 1997, medical science has been trying to solve the mystery of NSF/NSD. But until recently, little was known about the causes of NSF/NSD and even less about its treatment. However, in 2006 research into NSF/NSD finally yielded some results. In a study conducted by Dr. T. Grobner, it was found that of 9 people with NSF/NSD, 5 of the patients had undergone MRIs involving the use of Ominscan Contrast Dye, a gadolinium based contrast agent manufactured by GE. This study was followed by others that showed similarly strong connections between NSF/NSD and the use of gadolinium based contrast agents in people with kidney disease. That year, the FDA warned healthcare professionals that gadolinium based agents had been tied to multiple cases of NSF/NSD. Then in 2007, the FDA went even further and requested that the manufacturers of the five gadolinium based contrast agents used in MRIs include a boxed warning on product labels highlighting the risk they posed to patients with kidney problems.